Frequency of and rationales for the combined use of electroconvulsive therapy and antiepileptic drugs in Austria and the literature

2009 ◽  
Vol 10 (4-3) ◽  
pp. 836-845 ◽  
Author(s):  
Paul Rubner ◽  
Stefan Koppi ◽  
Andreas Conca
Keyword(s):  
Antiepileptic Drugs ◽  
Electroconvulsive Therapy ◽  
Combined Use

scholarly journals Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis

Heliyon ◽  
2017 ◽  
Vol 3 (11) ◽  
pp. e00429 ◽  
Author(s):  
Saeed Ahmed ◽  
Ali Mahmood Khan ◽  
Hema Madhuri Mekala ◽  
Hema Venigalla ◽  
Rizwan Ahmed ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Meta Analysis ◽  
Treatment Resistant ◽  
Combined Use

Comparison of Psychiatric Disorders Between Levetiracetam Combined With Lacosamide and Perampanel

2021 ◽  
Author(s):  
Satoru Matsunuma ◽  
Shigeki Sunaga ◽  
Akira Hoshiai ◽  
Takao Arai ◽  
Hiroyuki Jimbo ◽  
...  
Keyword(s):  
Psychiatric Disorders ◽  
Antiepileptic Drugs ◽  
Medical Records ◽  
Medical Center ◽  
Combined Use ◽  
Number Of Patients ◽  
Significant Difference ◽  
Patients With Epilepsy ◽  
Time To Onset ◽  
Dose Dependent

Abstract Background The number of patients with epilepsy receiving perampanel or lacosamide as an add-on treatment following levetiracetam treatment has increased. Although levetiracetam causes psychiatric disorders, it is unclear whether they occur with the combined use of these antiepileptic drugs.Objective To determine the frequency of psychiatric disorders in patients using lacosamide or perampanel as an add-on therapy to levetiracetam. Setting A single-center retrospective cohort study. Methods Patients who received levetiracetam, lacosamide, and perampanel between April 1, 2014 and April 30, 2019 in Hachioji Medical Center were selected. They were classified into the levetiracetam+lacosamide or levetiracetam+perampanel group. Medical records from the start of combination therapy contained patient background and the incidence of psychiatric disorders. Main outcome measure Onset of psychiatric disorders. Results Forty-four patients used levetiracetam+lacosamide and 50 used levetiracetam+perampanel. The incidence of psychiatric disorders was significantly lower (p = 0.000047) with levetiracetam+lacosamide (6.8%) than with levetiracetam+perampanel (46%). The time to the onset of psychiatric disorders was within 1 month of dose initiation or increase in one case (33.3%) with levetiracetam+lacosamide and 16 cases (76.2%) with levetiracetam+perampanel. The median time to onset was 56 and 6.5 days with levetiracetam+lacosamide and levetiracetam+perampanel, respectively. There was no significant difference in antiepileptic drug dosages owing to the presence or absence of psychiatric disorders. Conclusion As the frequency of psychiatric disorders was higher with levetiracetam+perampanel therapy, levetiracetam+lacosamide may be preferable. These disorders tended to develop within 1 month of therapy and were not dose-dependent. Antiepileptic drugs should be cautiously prescribed to avoid psychiatric disorders.

FEATURES OF MODERN PHARMACOTHERAPY OF EPILEPTIC STATUS

2021 ◽  
pp. 31-38
Author(s):  
Tokareva N.G. ◽  
Ignatieva O.I.
Keyword(s):  
Status Epilepticus ◽  
Side Effects ◽  
Antiepileptic Drugs ◽  
Refractory Status Epilepticus ◽  
International Standards ◽  
Correct Selection ◽  
Treatment And Prevention ◽  
New Antiepileptic Drugs ◽  
Combined Use ◽  
Special Approach

In the presented review of the literature, the most significant problems of modern pharmacotherapy of status epilepticus are indicated. The urgency of treatment of status epilepticus is confirmed by its frequency and ineffectiveness of traditional drugs (benzodiazepines, hydantoins, barbiturates), which have a number of side effects from the cardiovascular and respiratory systems. In Russian intensive care medicine, treatment of status epilepticus is carried out in accordance with international standards and recommendations. For a number of years, the injectable form of valproate has proven its effectiveness, including in pediatric practice. In comparative studies, phenytoin, valproate and levetiracetam are safe and equally effective in treating status epilepticus. A particular difficulty in therapy is caused by benzodiapine-resistant status epilepticus and refractory, which requires consideration of the possibility of using a combination of antiepileptic drugs. The review of foreign and domestic sources presents the results of clinical studies that allow the use of new antiepileptic drugs, which can effectively stop status epilepticus already in the early stages. New antiepileptic drugs are especially relevant in the treatment of patients refractory to drug treatment. However, treatment with antiepileptic drugs does not always show its effectiveness in refractory and super-refractory status epilepticus, which requires new approaches in complex treatment. The tolerance of drugs and the frequency of side effects are important for patients, since most of them require long-term combined use. Correct selection of antiepileptic drugs increases the level of compliance. A special approach requires the treatment of status epilepticus in the context of palliative care and comorbid pathology. In the treatment and prevention of status epilepticus, surgical treatment and the use of a ketogenic diet can be considered.

Combined use of clozapine and ECT: a review

2015 ◽  
Vol 27 (3) ◽  
pp. 131-142 ◽  
Author(s):  
Sandeep Grover ◽  
Nandita Hazari ◽  
Natasha Kate
Keyword(s):  
Electroconvulsive Therapy ◽  
Case Reports ◽  
Case Series ◽  
Side Effect Profile ◽  
Augmentation Therapy ◽  
Treatment Resistant ◽  
Short Term ◽  
Open Label ◽  
Combined Use

ObjectiveThis paper aims to review the available evidence for the use of clozapine and electroconvulsive therapy (ECT) in combination.MethodologyElectronic searches were carried out to identify reports describing the combined use of clozapine and ECT.ResultsForty reports including 208 patients were identified. The majority of reports were in the form of case reports and case series, with few retrospective and open-label studies. The majority of patients were aged between 18 and 65 years and diagnosed with schizophrenia or schizoaffective disorder. Most of the patients refractory to clozapine were started on ECT as an augmentation therapy; however, in some reports, both ECT and clozapine were started concurrently, and in few cases clozapine was started after ECT. In terms of effectiveness, 37.5–100% patients improved in short-term, and sustained long-term improvement (3 weeks to 24 months) was described in few studies. In terms of the side-effect profile, five patients each had delirium and tachycardia and only four patients were described to have prolonged seizures. Overall, the combination was considered effective and safe.ConclusionThere is evidence for the effectiveness and safety of the clozapine–ECT combination and it should be used in patients with treatment-resistant schizophrenia who do not respond to clozapine.

scholarly journals Antiepileptic drugs with nootropic effect is the best choice if you need a comprehensive treatment for comorbid disorders

2021 ◽  
Vol 17 (7) ◽  
pp. 27-35
Author(s):  
Yu.I. Goransky ◽  
V.M. Hertsev ◽  
M.Yu. Serhieieva
Keyword(s):  
Antiepileptic Drugs ◽  
Cognitive Impairments ◽  
Optimal Choice ◽  
Comprehensive Treatment ◽  
Traumatic Injuries ◽  
Beneficial Effects ◽  
Combined Use ◽  
Patients With Epilepsy ◽  
Methods Of Treatment ◽  
Nootropic Effect

The article presents the results of a review devoted to the search for optimal methods of treatment in patients with epilepsy with concomitant cognitive impairments. It has been established that antiepileptic drugs with a nootropic effect are the most optimal choice in terms of compliance with the therapy, as well as reducing the frequency of side effects in the case of monotherapy in comparison with the combined use of nootropics and antiepileptic drugs. Levetiracetam is one of the drugs of choice with proven beneficial effects on cognitive function in patients with epilepsy. Due to high safety profile, it can be recommended for use in elderly patients with epilepsy, including for the termination of status epilepticus, and can also be used in cases of combination of Alzheimer’s disease with epilepsy. A promising direction for further researches is to study the possibilities of using levetiracetam in traumatic injuries of the nervous system.

scholarly journals Evaluation of the effectiveness of electroconvulsive therapy in the treatment of psychosis in a patient with epilepsy. Clinical case

2021 ◽  
Vol 13 (1S) ◽  
pp. 79-87
Author(s):  
T. V. Dokukina ◽  
F. P. Khlebokazov ◽  
I. I. Khvostova ◽  
N. N. Misyuk ◽  
K. A. Bondar ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Antiepileptic Drugs ◽  
Electroconvulsive Therapy ◽  
Successful Treatment ◽  
Clinical Condition ◽  
Clinical Case ◽  
Epileptic Seizures ◽  
Drug Resistant ◽  
Drug Resistant Epilepsy ◽  
Progressive Course

The results of successful treatment of schizophrenic psychosis with persistent catatonic symptoms, refusal to eat in a patient with epilepsy are presented. In view of the progressive course of the disease, the lack of dynamics from the ongoing drug treatment, the method of electroconvulsive therapy was applied. Epileptic seizures and visual signs of brain epileptization were absent with the development of psychosis. As a result of the course of electroconvulsive therapy (9 procedures), the patient's clinical condition improved significantly. This observation illustrates the possibility of using electroconvulsive therapy in combination with antipsychotics and antiepileptic drugs as an alternative method for treating drug-resistant epilepsy.

Sign in / Sign up

Export Citation Format

Share Document